Nazione: Irlanda
Lingua: inglese
Fonte: HPRA (Health Products Regulatory Authority)
IRINOTECAN HYDROCHLORIDE TRIHYDRATE
Beacon Pharmaceuticals Ltd
IRINOTECAN HYDROCHLORIDE TRIHYDRATE
20 Mg/Ml
Concentrate for Soln for Inf
Product subject to prescription which may not be renewed (A)
Withdrawn
2012-12-14
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Camrata 20 mg/ml concentrate for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of concentrate contains 20 mg irinotecan hydrochloride trihydrate (equivalent to 17.33 mg/ml irinotecan). Each 2ml vial contains 40 mg of irinotecan hydrochloride trihydrate. Each 5ml vial contains 100 mg of irinotecan hydrochloride trihydrate. Excipients: Also contains sorbitol (E420) 45 mg/ml and sodium (see Section 4.4) For a full list of excipients, see Section 6.1 3 PHARMACEUTICAL FORM Concentrate for solution for infusion. A clear, pale yellow solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Camrata is indicated for the treatment of patients with advanced colorectal cancer: • In combination with 5-fluorouracil (5-FU) and folinic acid (FA) in patients without prior chemotherapy for advanced disease, • As a single agent in patients who have failed an established 5-FU containing treatment regimen. Camrata in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer, who had not received prior treatment for metastatic disease or after failure of irinotecan-including cytotoxic therapy (see Section 5.1). Camrata in combination with 5-FU, FA and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum. Camrata in combination with capecitabine with or without bevacizumab is indicated for first-line treatment of patients with metastatic colorectal carcinoma. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For use in adults only. Camrata should be infused into a peripheral or central vein. See Section 6.6 for instructions on the preparation and use o Leggi il documento completo